Xiaofen Ye
YOU?
Author Swipe
View article: Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22
Rational design of potent small-molecule SMARCA2/A4 degraders acting via the recruitment of FBXO22 Open
View article: Epiregulon: Single-cell transcription factor activity inference to predict drug response and drivers of cell states
Epiregulon: Single-cell transcription factor activity inference to predict drug response and drivers of cell states Open
View article: Inspiratory capacity and inhalation techniques evaluated and training by digital therapy comprehensive management platform in COPD patients
Inspiratory capacity and inhalation techniques evaluated and training by digital therapy comprehensive management platform in COPD patients Open
Background Inhalation therapy is the main pharmaceutical treatment for patients with chronic obstructive pulmonary disease (COPD), but the improper selection and incorrect use of inhalation devices are widespread. The digital therapy compr…
View article: Rational design of potent small molecule SMARCA2/A4(BRM/BRG1) degraders acting via the recruitment of FBXO22
Rational design of potent small molecule SMARCA2/A4(BRM/BRG1) degraders acting via the recruitment of FBXO22 Open
Target-anchored monovalent degraders are more drug-like than their bivalent counterparts, Proteolysis Targeting Chimeras (PROTACs), while offering greater target specificity control than the E3 ligase-anchored monovalent degraders, also kn…
View article: Rational design of potent small molecule SMARCA2/A4 (BRM/BRG1) degraders acting via the recruitment of FBXO22
Rational design of potent small molecule SMARCA2/A4 (BRM/BRG1) degraders acting via the recruitment of FBXO22 Open
Target-anchored monovalent degraders are more drug-like than their bivalent counterparts, Proteolysis Targeting Chimeras (PROTACs), while offering greater target specificity control than the E3 ligase-anchored monovalent degraders, also kn…
View article: Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs
Tissue distribution and retention drives efficacy of rapidly clearing VHL-based PROTACs Open
Background Proteolysis-targeting chimeras (PROTACs) are being developed for therapeutic use. However, they have poor pharmacokinetic profiles and their tissue distribution kinetics are not known. Methods A typical von Hippel-Lindau tumor s…
View article: PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models
PROTACs Targeting BRM (SMARCA2) Afford Selective <i>In Vivo</i> Degradation over BRG1 (SMARCA4) and Are Active in BRG1 Mutant Xenograft Tumor Models Open
The identification of VHL-binding proteolysis targeting chimeras (PROTACs) that potently degrade the BRM protein (also known as SMARCA2) in SW1573 cell-based experiments is described. These molecules exhibit between 10- and 100-fold degrad…
View article: Demethylzeylasteral (T-96) Alleviates Allergic Asthma via Inhibiting MAPK/ERK and NF-κB Pathway
Demethylzeylasteral (T-96) Alleviates Allergic Asthma via Inhibiting MAPK/ERK and NF-κB Pathway Open
Introduction: Demethylzeylasteral (T-96), a new extract of Tripterygium wilfordii Hook F, exerted immunomodulatory properties in autoimmune diseases, but its effect on airway inflammatory diseases remains unclear. Our …
View article: Prediction of papillary thyroid metastases to the central compartment: proposal of a model taking into consideration other thyroid conditions
Prediction of papillary thyroid metastases to the central compartment: proposal of a model taking into consideration other thyroid conditions Open
Objective To construct risk prediction models for cervical lymph node metastasis (CLNM) of papillary thyroid carcinoma (PTC) under different thyroid disease backgrounds and to analyze and compare risk factors among different groups. Method…
View article: Epiregulon: Inference of single-cell transcription factor activity to predict drug response and drivers of cell state
Epiregulon: Inference of single-cell transcription factor activity to predict drug response and drivers of cell state Open
Transcription factors (TFs) and transcriptional coregulators represent an emerging class of therapeutic targets in oncology. Gene regulatory networks (GRNs) can be used to evaluate pharmacological agents targeting these factors and to iden…
View article: Integration of Technical Teaching and Assessment Based on the Four E Framework
Integration of Technical Teaching and Assessment Based on the Four E Framework Open
In higher education, the evaluation of students' academic performance has always been a very challenging task. The lecturer's summative evaluation of the students is often carried out at the end of the semester or after the phased study. T…
View article: Nurses in China lack knowledge of inhaler devices: A cross-sectional study
Nurses in China lack knowledge of inhaler devices: A cross-sectional study Open
Objective: To understand the level of knowledge about inhaler devices among medical staff. Methods: This study evaluated the knowledge of inhalation therapy and the use of inhaler devices among nurses in China. We administered a new self-d…
View article: Data from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Data from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
Approximately half of EGFR-mutant non–small cell lung cancer (NSCLC) patients treated with small-molecule EGFR kinase inhibitors develop drug resistance associated with the EGF receptor (EGFR) T790M “gatekeeper” substitution, prompt…
View article: Supplementary Dataset 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Dataset 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
XLSX file - 242K, Ambit kinome profiling with 0.5 μM G�6976.
View article: Supplementary Figure 5 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 5 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 248K, PKC412 is a reversible EGFR T790M inhibitor.
View article: Supplementary Figure 7 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 7 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 25K, Pharmacokinetic parameters of PKC412.
View article: Supplementary Figure 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 28K, PKC412 is the most selective EGFR T790M inhibitor tested versus EGFR wild-type.
View article: Supplementary Figure 4 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 4 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 142K, EGFR sequencing of the PC-9 ER clone.
View article: Supplementary Figure 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 2 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 28K, PKC412 is the most selective EGFR T790M inhibitor tested versus EGFR wild-type.
View article: Supplementary Figure 5 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 5 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 248K, PKC412 is a reversible EGFR T790M inhibitor.
View article: Supplementary Figure 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 528K, G�6976 inhibits EGFR mutant NSCLC cells independently of PKC inhibition.
View article: Supplementary Figure 7 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 7 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 25K, Pharmacokinetic parameters of PKC412.
View article: Supplementary Figure 6 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 6 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 21K, Body weight measurement for EGFR T790M xenografts.
View article: Supplementary Dataset 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Dataset 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
XLSX file - 109K, Tumor cell line profiling of G�6976 sensitivity.
View article: Supplementary Figure 8 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 8 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 78K, Efficacy of PKC412 on tumor growth and signaling in EGFRL858R+T790M transgenic mice.
View article: Supplementary Methods and Figure Legend from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Methods and Figure Legend from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 130K
View article: Supplementary Figure 3 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 3 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 177K, Comparison of EGFR T790M inhibitors in NR6 cell lines expressing WT EGFR.
View article: Supplementary Figure 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 1 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 528K, G�6976 inhibits EGFR mutant NSCLC cells independently of PKC inhibition.
View article: Supplementary Methods and Figure Legend from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Methods and Figure Legend from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 130K
View article: Supplementary Figure 6 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M
Supplementary Figure 6 from Noncovalent Wild-type–Sparing Inhibitors of EGFR T790M Open
PDF file - 21K, Body weight measurement for EGFR T790M xenografts.